Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia

BMC Psychiatry
Saki HattoriYoshio Hirayasu

Abstract

There are interindividual differences in the adverse effects of atypical antipsychotics, which include autonomic nervous system (ANS) dysfunction. Accordingly, to clarify the interindividual differences in the adverse effects of specific atypical antipsychotics in schizophrenia, we investigated the association between ANS dysfunction and ATP-binding cassette transport sub-family B member 1 (ABCB1) gene polymorphisms in patients with schizophrenia. In total, 233 Japanese patients with schizophrenia participated in this study. All of the participants received an atypical antipsychotic as monotherapy: 89 participants received risperidone, 69 olanzapine, 48 aripiprazole, and 27 quetiapine. ANS activity was assessed by means of a power spectral analysis of heart rate variability. Four single nucleotide polymorphisms (SNPs) in ABCB1 (rs1045642, rs1128503, rs2032582, and rs2235048) were genotyped using the TaqMan method. For aripiprazole, sympathetic and total autonomic nervous activities were significantly lower in the rs1045642 T allele carrier-rs2235048 C allele carrier group than in the rs1045642 non-T allele carrier-rs2235048 non-C allele carrier group. In addition, in the aripiprazole group, the T-C-T-A haplotype (rs1045642-rs22...Continue Reading

References

May 1, 1977·Medical & Biological Engineering & Computing·O RompelmanR I Kitney
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1995·Annual Review of Genetics·M M GottesmanI Pastan
Sep 22, 1999·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·T MatsumotoT Moritani
May 29, 2002·Life Sciences·David W BoultonJohn S Markowitz
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jong-Hoon KimYong Sik Kim
Aug 7, 2004·Bioinformatics·J C BarrettM J Daly
Mar 15, 2005·Journal of Electromyography and Kinesiology : Official Journal of the International Society of Electrophysiological Kinesiology·Toshio MoritaniNarumi Nagai
Jun 17, 2006·European Journal of Applied Physiology·Tetsuya KimuraToshio Moritani
Dec 23, 2006·Science·Chava Kimchi-SarfatyMichael M Gottesman
Jan 12, 2007·Journal of Psychosomatic Obstetrics and Gynaecology·Tamaki MatsumotoNoriyuki Tatsumi
Feb 26, 2009·Schizophrenia Research·Jun-Sheng WangC Lindsay Devane
Jun 6, 2009·Psychiatry and Clinical Neurosciences·Mami FujibayashiToshio Moritani
Nov 17, 2009·International Journal of Cardiology·Julian F ThayerJos F Brosschot
Jul 6, 2010·Neuropharmacology·Katrin M KirschbaumUlrich Schmitt
Sep 17, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·A BirkhoferG Schmidt
Feb 21, 2013·Journal of Clinical Psychopharmacology·Wei-Lieh HuangCheryl C H Yang
May 7, 2013·European Archives of Psychiatry and Clinical Neuroscience·Masa IedaJun Horiguchi
Jan 21, 2015·Psychiatry and Clinical Neurosciences·Toshiya Inada, Ataru Inagaki
Jul 2, 2015·Clinical Pharmacokinetics·Frederik VandenbergheChin B Eap
Sep 16, 2015·Acta Psychiatrica Scandinavica·D S QuintanaO A Andreassen
Jan 6, 2016·The British Journal of Psychiatry : the Journal of Mental Science·Annika ClamorJulian Koenig
Jul 16, 2017·Schizophrenia Research·Saki HattoriYoshio Hirayasu

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

Haploview
SPSS

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here